Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its second quarter 2025 financial results announcement for August 12, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register at least one day in advance to receive dial-in information. The webcast will be archived for 30 days on Acumen's investor relations website.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti per la malattia di Alzheimer, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025.
L'azienda terr脿 una conferenza telefonica e una trasmissione audio in diretta alle 8:00 a.m. ET per discutere aggiornamenti aziendali e performance finanziarie. I partecipanti devono registrarsi almeno un giorno prima per ricevere le informazioni di accesso. La registrazione della trasmissione sar脿 disponibile per 30 giorni sul sito web delle relazioni con gli investitori di Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmac茅utica en etapa cl铆nica enfocada en desarrollar tratamientos para la enfermedad de Alzheimer, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025.
La compa帽铆a realizar谩 una llamada conferencia y una transmisi贸n de audio en vivo a las 8:00 a.m. ET para discutir actualizaciones comerciales y desempe帽o financiero. Los participantes deben registrarse con al menos un d铆a de anticipaci贸n para recibir la informaci贸n de acceso. La transmisi贸n quedar谩 archivada por 30 d铆as en el sitio web de relaciones con inversionistas de Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS)電� 鞎岇笭頃橃澊毹鸽硲 旃橂鞝� 臧滊皽鞐� 歆戩頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 12鞚�搿� 鞓堨爼頄堨姷雼堧嫟.
须岇偓电� 霃欕秬 響滌鞁� 旮办 鞓れ爠 8鞁�鞐� 靷梾 鞐呺嵃鞚错姼 氚� 鞛 靹标臣毳� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滉臣 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 彀戈皜鞛愲姅 鞝戩啀 鞝曤炒毳� 氚涥赴 鞙勴暣 斓滌唽 頃橂（ 鞝勳棎 靷爠 霌彪頃挫暭 頃╇媹雼�. 鞗轨簮鞀ろ姼電� Acumen 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐� 30鞚缄皠 鞎勳勾鞚措笇霅╇媹雼�.
Acumen Pharmaceuticals (NASDAQ : ABOS), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de traitements contre la maladie d'Alzheimer, a programm茅 l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le 12 ao没t 2025.
La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une diffusion audio en direct 脿 8h00 ET pour discuter des mises 脿 jour commerciales et des performances financi猫res. Les participants doivent s'inscrire au moins un jour 脿 l'avance pour recevoir les informations d'acc猫s. La diffusion sera archiv茅e pendant 30 jours sur le site des relations investisseurs d'Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien gegen Alzheimer konzentriert, hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 12. August 2025 geplant.
Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um Gesch盲ftsaktualisierungen und finanzielle Leistungen zu besprechen. Teilnehmer m眉ssen sich mindestens einen Tag im Voraus registrieren, um die Einwahlinformationen zu erhalten. Der Webcast wird f眉r 30 Tage auf der Investor-Relations-Website von Acumen archiviert.
- None.
- None.
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS) (鈥淎cumen鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer鈥檚 disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.听听
To participate in the live conference call, please register using this鈥� After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.鈥赌�
The webcast audio will be available via this鈥�赌�
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at听.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A尾Os) for the treatment of Alzheimer鈥檚 disease (AD). Acumen鈥檚 scientific founders pioneered research on A尾Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer鈥檚 disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic A尾Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer鈥檚 disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme鈥檚 proprietary ENHANZE庐听drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD鈩�) therapy for Alzheimer鈥檚 disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit .
Investors:
Alex Braun
Media:听
听
FAQ
When will Acumen Pharmaceuticals (NASDAQ: ABOS) report Q2 2025 earnings?
How can investors access Acumen Pharmaceuticals' Q2 2025 earnings call?
What is Acumen Pharmaceuticals' main focus in drug development?
Where can investors find the replay of Acumen's Q2 2025 earnings webcast?
